La cadena de opciones muestra datos clave de las opciones de acciones de Gain Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Gain Therapeutics..

Gain Therapeutics (NASDAQ:GANX) Bolsa, Cadena de Opciones

Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

AZTR

GANX

SILO

Descubre las últimas transacciones de insiders en penny stocks como ALZN, GANX, AZTR y SILO. ¡Aprovecha esta información privilegiada ahora!

Compras de insiders de penny stocks: ALZN, GANX, AZTR, SILO

Gain Therapeutics Inc

WIIM

Cue Biopharma shares are trading lower. The company reported Q3 financial results.

Jefferies analyst Corey Tarlowe maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Buy and lowers the price target from $110 to $90.

Price Target

Analyst Ratings

Jefferies Maintains Buy on Dollar Gen, Lowers Price Target to $90

On Thursday, Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) announced the termination of its merger agreement with Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>), citing <a target="_blank" href="https://www.benzinga.com/news/buybacks/24/11/41971497/tapestry-and-capri-call-off-8-5b-deal-amid-legal-hurdles" rel="noreferrer noopener">uncertainty in the legal process.</a>
Following the termination of the merger agreement, Tapestry said it will redeem $6.1 billion in senior notes tied to the acquisition, paying 101% of their principal amount plus accrued interest, as per the Special Mandatory Redemption clause. Tapestry will also reimburse Capri $45 million for transaction-related expenses.
Here are the analysts&#8217; takes <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41550527/why-capri-holdings-stock-is-falling-today" rel="noreferrer noopener">on the&nbsp;termination news</a>:
Telsey Advisory Group: Analyst Dana Telsey maintained the Market Perform rating on Capri Holdings, lowering <a target="_blank" href="https://www.benzinga.com/quote/CPRI/analyst-ratings" rel="noreferrer noopener">the price forecast to $23 from $26</a>. Considering the string of disappointing results over the past several quarters, the analyst trimmed the price forecast.
Per the analyst, the company saw some initial successes, but the campaigns didn&#8217;t connect well with its core customers. It raised price points too quickly. Additionally, the brand reduced its signature products and introduced too much fashion, leading to deeper promotions to drive sales.
However, for Tapestry, the analyst raised the price forecast to $67 from $58, <a target="_blank" href="https://www.benzinga.com/quote/TPR/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>. Telsey is optimistic about earnings growth from the new buyback authorization and the company&#8217;s strong balance sheet.
The analyst sees no near-term acquisitions while focusing on improving Kate&#8217;s performance.
Meanwhile, the Coach brand remains resilient, with a 2% increase in constant currency last quarter, the analyst writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014985/matt-gaetz-to-be-confirmed-as-attorney-general-in-a-trump-administration-not-so-fast-polymarket-traders-say" rel="noreferrer noopener">Matt Gaetz To Be Confirmed As Attorney General In A Trump Administration? Not So Fast, Polymarket Traders Say</a>
Guggenheim: Analyst Robert Drbul maintained a Neutral rating on Capri Holdings, citing the company&#8217;s deteriorating results over the past few years. The analyst pointed out &#8220;multiple missteps&#8221; by the company, including focus on younger consumers, rapid price increases, and reduced promotions.
Drbul also criticized the reduction of signature styles and overemphasis on &#8220;fashion&#8221; at Michael Kors. At Versace, the shift toward luxury/quality alienated the aspirational consumer by removing statement items. The analyst lowered FY25/FY26 EPS estimates to $1.50/$2.00, down from $1.85/$2.10. Per Drbul, Capri&#8217;s current low valuation could attract offers.
Drbul reiterated the Buy rating on Tapestry, raising the price forecast to $70 from $60. The analyst notes Tapestry will focus on strengthening Coach and Kate Spade, not pursuing acquisitions for now. With the Capri merger behind, Drbul sees value in Tapestry&#8217;s current portfolio.
The company is expected to benefit from pricing power in FY25 and may reach a 19% operating margin, with long-term potential to return to pre-COVID margins, driven by DTC growth and expansion in Asia, Drbul writes.
JP Morgan: Analyst Matthew R. Boss reiterated the Neutral rating on Capri Holdings, with a price forecast of $15. The analyst projects FY25 EPS of $1.44, 17% below consensus, with a 14% year over year revenue decline and a 45bps gross margin contraction.&nbsp;
For the second half of 2025, the analyst projects revenues to be down 13% (an improvement from the first half&#8217;s -15%), gross margins to decrease by 10bps year over year (compared to the first half&#8217;s -80bps).
Capri Holdings&#8217; shift to a higher direct-to-consumer sales mix has boosted full-price selling, but also increased operating expenses, Boss writes. The analyst warns that with limited opportunities to cut SG&amp;A costs, this could be challenging amid a slowing top-line growth.
Price Action: CPRI shares are trading higher by 1.80% to $20.89 at last check Friday, while TPR shares are trading lower by 0.98% to $57.26.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011697/bitcoin-hacker-sentenced-to-5-years-for-laundering-billions-in-crypto-theft" target="_blank" rel="noreferrer noopener">Bitcoin Hacker Sentenced To 5 Years For Laundering Billions In Crypto Theft</a></li>
</ul>

Analyst Color

Equities

Reiteration

General

CPRI

Tapestry Poised For Solid Growth After Capri Merger Termination, Analysts Cite Struggles And Missteps At Capri

TD Cowen analyst Krish Sankar maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and lowers the price target from $250 to $230.

AMAT

TD Cowen Maintains Buy on Applied Mat, Lowers Price Target to $230

Whales with a lot of money to spend have taken a noticeably bullish stance on Morgan Stanley.
Looking at options history for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) we detected 23 trades.
If we consider the specifics of each trade, it is accurate to state that 56% of the investors opened trades with bullish expectations and 26% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $332,437 and 16, calls, for a total amount of $1,219,604.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $185.0 for Morgan Stanley during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Morgan Stanley's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Morgan Stanley's significant trades, within a strike price range of $95.0 to $185.0, over the past month.
<h3>Morgan Stanley Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696369_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$140.00</td>
<td>$340.0K</td>
<td>3.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6.85</td>
<td>$5.15</td>
<td>$6.85</td>
<td>$185.00</td>
<td>$136.8K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$130.00</td>
<td>$125.2K</td>
<td>6.4K</td>
<td>293</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$14.9</td>
<td>$14.6</td>
<td>$14.75</td>
<td>$140.00</td>
<td>$103.2K</td>
<td>224</td>
<td>75</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$115.00</td>
<td>$85.0K</td>
<td>7.3K</td>
<td>47</td>
</tr>
</tbody>
</table>

<h3>About Morgan Stanley</h3>
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.
In light of the recent options history for Morgan Stanley, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Morgan Stanley Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,092,834, with MS's price up by 0.76%, positioned at $133.44.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Morgan Stanley</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $128.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Morgan Stanley, which currently sits at a price target of $121. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Morgan Stanley, maintaining a target price of $135. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Morgan Stanley, maintaining a target price of $135. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Underweight rating for Morgan Stanley, targeting a price of $107. 
&#x2A; An analyst from Wells Fargo upgraded its action to Equal-Weight with a price target of $142. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Morgan Stanley, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on Morgan Stanley: Analyzing the Surge in Options Activity

Investors with significant funds have taken a bullish position in Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in LDOS usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for Leidos Holdings. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 50% being bullish and 50% bearish. Of all the options we discovered, 7 are puts, valued at $974,530, and there was a single call, worth $29,500.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $170.0 for Leidos Holdings during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Leidos Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Leidos Holdings's significant trades, within a strike price range of $130.0 to $170.0, over the past month.
<h3>Leidos Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696364_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.4</td>
<td>$4.8</td>
<td>$5.4</td>
<td>$155.00</td>
<td>$346.1K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$8.4</td>
<td>$7.0</td>
<td>$8.4</td>
<td>$130.00</td>
<td>$168.0K</td>
<td>1.5K</td>
<td>77</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.7</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$165.00</td>
<td>$148.7K</td>
<td>127</td>
<td>133</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$155.00</td>
<td>$111.9K</td>
<td>0</td>
<td>232</td>
</tr>
<tr>
<td>LDOS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.1</td>
<td>$5.8</td>
<td>$7.6</td>
<td>$160.00</td>
<td>$96.5K</td>
<td>202</td>
<td>289</td>
</tr>
</tbody>
</table>

<h3>About Leidos Holdings</h3>
Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health markets, both domestically and internationally. Company customer includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in three reportable segments; Defense Solutions, Civil, and Health. Defense Solutions provides technologically latest services, solutions, and products to a broad customer base. It generates key revenue from Defense Solutions.
After a thorough review of the options trading surrounding Leidos Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Leidos Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,765,461, the LDOS's price is down by -5.9%, now at $158.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What Analysts Are Saying About Leidos Holdings</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $212.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Leidos Holdings, which currently sits at a price target of $200. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Leidos Holdings with a target price of $210. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Leidos Holdings, which currently sits at a price target of $230. 
&#x2A; An analyst from Baird persists with their Outperform rating on Leidos Holdings, maintaining a target price of $218. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Leidos Holdings, maintaining a target price of $205. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Leidos Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

LDOS

Unpacking the Latest Options Trading Trends in Leidos Holdings

High-rolling investors have positioned themselves bullish on NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in NN often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for NextNav. This is not a typical pattern.
The sentiment among these major traders is split, with 69% bullish and 23% bearish. Among all the options we identified, there was one put, amounting to $105,000, and 12 calls, totaling $504,800.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $3.0 to $17.0 for NextNav over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for NextNav's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NextNav's whale activity within a strike price range from $3.0 to $17.0 in the last 30 days. 
<h3>NextNav Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731696359_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.4</td>
<td>$11.3</td>
<td>$11.4</td>
<td>$3.00</td>
<td>$125.4K</td>
<td>2.9K</td>
<td align="right">110</td>
</tr>
<tr>
<td>NN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.75</td>
<td>$15.00</td>
<td>$105.0K</td>
<td>26</td>
<td align="right">600</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$7.2</td>
<td>$6.7</td>
<td>$6.7</td>
<td>$17.00</td>
<td>$46.9K</td>
<td>566</td>
<td align="right">70</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.9</td>
<td>$6.7</td>
<td>$7.84</td>
<td>$15.00</td>
<td>$39.4K</td>
<td>1.7K</td>
<td align="right">310</td>
</tr>
<tr>
<td>NN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.1</td>
<td>$12.00</td>
<td>$39.3K</td>
<td>693</td>
<td align="right">98</td>
</tr>
</tbody>
</table>

<h3>About NextNav</h3>
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation and Timing services in the absence of GPS.
In light of the recent options history for NextNav, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of NextNav</h3>
<ul>
<li>Trading volume stands at 568,994, with NN's price up by 0.85%, positioned at $14.27.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 117 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NextNav options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in NextNav

TD Cowen analyst Lance Vitanza maintains Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) with a Hold and lowers the price target from $20 to $16.

INSG

TD Cowen Maintains Hold on Inseego, Lowers Price Target to $16

Jefferies analyst Corey Tarlowe maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Buy and raises the price target from $95 to $105.

Jefferies Maintains Buy on BJ's Wholesale Club, Raises Price Target to $105

TD Cowen analyst Bryan Bergin maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Buy and raises the price target from $230 to $240.

GLOB

TD Cowen Maintains Buy on Globant, Raises Price Target to $240

Jefferies analyst Corey Tarlowe maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $90 to $100.

Jefferies Maintains Buy on Walmart, Raises Price Target to $100

ABAT

American Battery Technology shares are trading lower. The company reported Q1 financial results.

TD Cowen analyst Doug Creutz maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Hold and raises the price target from $108 to $123.

TD Cowen Maintains Hold on Walt Disney, Raises Price Target to $123

Jefferies analyst Samad Samana maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and lowers the price target from $230 to $215.

NICE

Jefferies Maintains Buy on NICE, Lowers Price Target to $215

Goatseus Maximus (CRYPTO: GOAT) has seen impressive gains, climbing 35.3% over the past week. The rally places the AI meme coin at the forefront of the meme coin market, with traders <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41432283/move-over-dogecoin-shiba-inu-ai-meme-coin-goat-prints-over-3-million-in-profit-for-whale-t">anticipating further upside</a>. 
What Happened: The gain pushed its valuation to $1 billion placing it in the top ten of the meme coin board.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Goatseus Maximus (CRYPTO: GOAT)</td>
<td>&nbsp;$1.02</td>
<td>$1 Billion</td>
<td>&nbsp;+10.7%</td>
<td>&nbsp;+33%</td>
</tr>
<tr>
<td>Popcat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>)</td>
<td> $1.67</td>
<td>$1.6 Billion</td>
<td>&nbsp;-5.9%</td>
<td>&nbsp;+9.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With prices picking up steam, crypto trader Lucky <a href="https://x.com/LuckyXBT__/status/1857396228939518186">sees</a> GOAT price action quite similar to painful Popcat price action before its own "bull run."
Crypto trader Aylo predicts a bullish trend for the meme coin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Clear skies ahead for <a href="https://twitter.com/search?q=%24GOAT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOAT</a> Time to accelerate. <a href="https://t.co/dxX2iJi3FT">pic.twitter.com/dxX2iJi3FT</a>
&mdash; Aylo (@alpha_pls) <a href="https://twitter.com/alpha_pls/status/1857432408414364014?ref_src=twsrc%5Etfw">November 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1857424121669324907">sees</a> GOAT finally getting the breakout, saying the AI meme coin is showing resilience, with dips being quickly bought up, signaling strong support.
A breakout is <a href="https://x.com/DaanCrypto/status/1856996799669530793">anticipated</a> due to its bullish chart pattern. As a leader in the AI meme coin meta, GOAT still lacks a Binance spot listing, but such a development could further boost its momentum.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41917072/dogecoin-is-the-best-trump-proxy-industry-expert-claims">Dogecoin Is The &#8216;Best Trump Proxy,&#8217; Industry Expert Claims</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$POPCAT

AI Meme Coin GOAT Joins $1 Billion Club—Can It Target The Likes Of Dogecoin, Shiba Inu?

<a href="https://www.theverge.com/2024/11/15/24296351/microsoft-azure-openai-adobe-meta-customers-notepad">https://www.theverge.com/2024/11/15/24296351/microsoft-azure-openai-adobe-meta-customers-notepad</a>
Microsoft has been turning its OpenAI deal into a big business. Earlier this year, much of its Azure OpenAI offering, which provides access to OpenAI's language models, was contingent on a single big spender: TikTok. But I've now seen a recent list of its top customers, and it's clear that Microsoft has managed to diversify the business with a selection of major clients spending more than $1 million per month on Azure OpenAI services.
The software giant has a running list of what it considers its top 10 customers for Azure OpenAI, and I'm told Adobe and Meta both spent more than $1 million on Microsoft's AI services in September alone to make the top 10 customer list. Both Adobe and Meta are primarily using Microsoft's provisioned output for access to OpenAI models, which provides dedicated model processing capacity rather than Microsoft's token-based offerings for text and image generation.
Meta and Adobe's use of Azure OpenAI still falls far behind TikTok owner ByteDance's, though. The Information reported earlier this year that TikTok was <a href="https://www.theverge.com/2024/7/31/24210667/microsoft-tiktok-ai-openai-customer">paying Microsoft almost $20 million</a> per month to access OpenAI's models, making up nearly a quarter of the revenue generated by Azure OpenAI at the time. ByteDance's spending on Azure OpenAI is now less than 15 percent of Microsoft's Azure OpenAI business, thanks in part to a more diverse amount of customer spending on Microsoft's AI services and ByteDance spending less.
 &nbsp;

ADBE

MSFT

Reported Earlier, 'Microsoft's Top AI Customers Include Adobe And Meta/ TikTok Is Still Microsoft's Top Azure OpenAI Customer, Though' - The Verge

TD Cowen analyst Bryan Bergin maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Buy and raises the price target from $533 to $567.

TD Cowen Maintains Buy on Mastercard, Raises Price Target to $567

On Friday, Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42012383/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-elebsiran-combina" rel="noreferrer noopener">chronic hepatitis B</a>.
Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV).
The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths are associated with the disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39192084/why-is-infectious-disease-focused-vir-biotechnology-stock-trading-higher-on-wednesday" rel="noreferrer noopener">Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?</a>
Participants in the trial received tobevibart and elebsiran alone (doublet regimen) or in combination with PEG-IFNα (triplet regimen).
The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (&lt;1000 IU/mL) in both combination regimens.
The doublet and triplet regimens resulted in HBsAg loss at the end of treatment in 39% (7/18) and 46% (5/11) of participants with baseline HBsAg&lt;1,000 IU/mL, respectively.
The proportion of participants with varying baseline HBsAg levels who achieved HBsAg loss at the end of treatment was 16% (8/51) for the doublet and 22% (6/27) for the triplet regimen.
The doublet regimen resulted in 50% (4/8) of participants achieving HBsAg loss and anti-HBs seroconversion.
All participants with HBsAg loss at the end of treatment who received the triplet regimen achieved anti-HBs seroconversion (100%, 6/6).
Participants with HBsAg seroclearance at the end of treatment who meet eligibility criteria will discontinue treatment. A functional cure assessment will occur 24 weeks after treatment discontinuation.
Mark Eisner, Executive Vice President and Chief Medical Officer, Vir Biotechnology, said, &#8220;We are encouraged by these results and eagerly anticipate the functional cure data in 2025, as it will be decisive for the next steps of clinical development.&#8221;
Price Action: VIR stock is down 7.50% at $7.99 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012040/bristol-myers-faces-renewed-67-billion-lawsuit-over-drug-approval-delays-amid-resolved-trustee-issue" target="_blank" rel="noreferrer noopener">Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue</a></li>
</ul>

Biotech

Health Care

Movers

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?

<a href="https://www.nyserda.ny.gov/About/Newsroom/2024-Announcements/2024-11-15-NYSERDA-Issues-Advanced-Nuclear-Technologies-Request-For-Information#:~:text=Through%20this%20RFI%2C%20NYSERDA%20seeks,at%20Governor%20Kathy%20Hochul's%20direction.">https://www.nyserda.ny.gov/About/Newsroom/2024-Announcements/2024-11-15-NYSERDA-Issues-Advanced-Nuclear-Technologies-Request-For-Information#:~:text=Through%20this%20RFI%2C%20NYSERDA%20seeks,at%20Governor%20Kathy%20Hochul's%20direction.</a>
The New York State Energy Research and Development Authority (NYSERDA) today announced the issuance of a Request for Information (RFI) to gauge market interest in activities to develop advanced nuclear energy technologies in New York State. Through this RFI, NYSERDA seeks to identify entities that are currently pursuing or interested in a potential role in advanced nuclear energy development. Responses will help inform next steps following the Future Energy Economy Summit held in September at Governor Kathy Hochul's direction. Today's announcement demonstrates the State's continued commitment to remain at the forefront of emerging technologies to support the advancement of renewable energy resources and foster continued economic development.
NYSERDA President and CEO Doreen M. Harris said, "As local, national and international companies pursue nuclear energy for their on-site energy needs and the federal government signals interest in investing in this resource, we recognize that now is the time to position New York to fully engage this new sector that can drive significant economic development. Understanding the status of potential opportunities through this RFI will enable us to begin developing strategic partnerships and initiatives for complementary resources that will ultimately support the increased deployment of renewables as we work toward a zero-emission grid of the future."
Entities encouraged to respond include:
<ul>
<li>stakeholders who may be considering advanced nuclear solutions, such as users of large electric loads, industrial heat, and hydrogen – both those already active in New York and those considering establishing operations in New York;</li>
<li>supply chain companies that could provide critical components for development of advanced nuclear energy projects in New York;</li>
<li>potential host communities for nuclear reactors or supply chain projects</li>
<li>workforce development and training entities;</li>
<li>nuclear generation project developers;</li>
<li>financing/funding entities; and</li>
<li>research and development entities including laboratories, universities and private entities.</li>
</ul>
Generation project consideration associated with this RFI is restricted to New York Independent System Operator (NYSISO) Control Area Load <a href="https://www.nyiso.com/documents/20142/1397960/nyca_zonemaps.pdf/8c3807e1-5bab-ab44-3c71-2c8e61b5748b">Zones A-F <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a> which encompasses the area of New York State north and west of the lower Hudson Valley. All other aspects of the request including energy consumers, supply chain, and workforce apply to all parts of New York State.
Responses are preferred by December 16, 2024, to inform future engagement opportunities and planning. Responses may be submitted through NYSERDA's <a href="https://nyserda.seamlessdocs.com/f/AdvancedNuclearRFI">online portal <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a>. To view the RFI, visit NYSERDA's <a href="https://www.nyserda.ny.gov/Funding-Opportunities/Current-Funding-Opportunities">website</a>. Technical questions regarding this RFI may be directed to <a href="mailto:NuclearRFI@nyserda.ny.gov">NuclearRFI@nyserda.ny.gov <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a>.
Separate from today's announcement, later this year, NYSERDA also anticipates releasing a Final Blueprint for Consideration of Advanced Nuclear Technologies which was informed through public comments collected on the <a href="https://www.nyserda.ny.gov/summit">Draft Blueprint <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a> released at the Future Energy Economy Summit in September. The Summit put forward actions and needs associated with the simultaneous advancement of economic growth and a zero-emission electricity system in New York State, addressing increasing energy demands due to new economic development opportunities, acceleration of renewable energy development, as well as advancement of the technologies that will be necessary to enable a deeply renewable grid.
In addition to the RFI and the Final Blueprint for Consideration of Advanced Nuclear Energy Technologies in progress, other actions underway to inform planning for future energy needs include:
<ul>
<li><a href="https://energyplan.ny.gov/">New York's State Energy Plan <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a> update process, which commenced in September 2024 and will address all parts of the New York energy sector; and</li>
<li>The Public Service Commission Proceeding on Motion of the Commission to Implement a Large-Scale Renewable Program and a Clean Energy Standard ("0x40") <a href="https://documents.dps.ny.gov/public/MatterManagement/CaseMaster.aspx?Mattercaseno=15-E-0302">NYSDPS-DMM: Matter Master <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a>, which focuses on pursuing the target of zero emissions in the electricity sector by 2040, as set out in the Climate Leadership and Community Protection Act.</li>
</ul>
Information gathered through the request announced today is considered advisory in nature and any action by NYSERDA will be subject to all applicable laws, including procedural, regulatory, and environmental review requirements.

OKLO

"Advanced Nuclear Technologies Request For Information Announced To Gauge Market Interest; Seeks To Identify Entities Pursuing Or Interested In Potential Role In Development Of Advanced Nuclear Energy In New York" - NYSERDA

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and lowers the price target from $160 to $153.

ASND

TD Cowen Maintains Buy on Ascendis Pharma, Lowers Price Target to $153

Gain Therapeutics (GANX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

Buy Rating Affirmed for Gain Therapeutics on Promising Phase 1 Results and Solid Financial Outlook

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price target at $5.00...

Optimistic Buy Rating for Gain Therapeutics' GT-02287 Based on Promising Parkinson's Disease Treatment Potential

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price target at $8...

Buy Rating Affirmed for Gain Therapeutics' GT-02287 on Promising Phase 1 Results and Potential in Parkinson's Disease Treatment

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report), with a price...

Buy Rating Affirmed for Gain Therapeutics on GT-02287's Promising Parkinson's Disease Trial Data and Solid Financials

Gain Therapeutics ( ($GANX) ) has provided an update. Gain Therapeutics, Inc. revealed promising preclinical results for their drug candidate GT-02...

Gain Therapeutics Excels in Neurodegenerative Drug Trials

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Black Diamond Therapeutics (BDTX – Research Report),...

Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)

Gain Therapeutics (GANX) announced the presentation of a poster at the 36th EORTC-NCI-AACR, ENA, Symposium on molecular targets and cancer therapeu...

Gain Therapeutics presents data at 36th ENA symposium

"The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson'...

Gain Therapeutics reports Q3 EPS (17c), consensus (21c)

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS –&nbsp; Gain Therapeutics&nbsp;...

Closing Bell Movers: Applied Materials down 6% after earnings, guidance

Gain Therapeutics GAAP EPS of -$0.17

AKYA

ASTS

BDTX

CELC

DESP

DMRC

FLNT

HOOK

INKT

IZEA

MSGM

ORGN

POOL

SRFM

Press Releases

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics to Participate at Upcoming Investor Conferences

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

Comments

Gain Therapeutics

Gain Therapeutics (GANX) Opciones

Gain Therapeutics (NASDAQ:GANX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL